Masked T Cell Activators Cut PSA in 82% of Prostate Cancer Patients, Easing Toxicity
Updated
Updated · Futura · Jul 14
Masked T Cell Activators Cut PSA in 82% of Prostate Cancer Patients, Easing Toxicity
3 articles · Updated · Futura · Jul 14
Summary
High-dose masked T cell activators lowered PSA levels in 82% of patients with advanced, treatment-resistant prostate cancer, and nearly half showed tumor shrinkage at primary and metastatic sites.
VIR-5500 is designed to stay inactive outside tumors and switch on only in cancer tissue, aiming to avoid the dangerous whole-body inflammatory reactions seen with earlier T cell activators.
Most patients receiving the highest doses reported only mild inflammatory side effects, suggesting the masking approach may allow safer dosing while preserving anti-tumor activity.
More than 200 T cell activators are already in development across cancers and some viral infections, but these prostate data come from an ongoing phase I trial presented at a conference and still await peer review.
Could cancer cells evolve to keep these new 'smart' drugs permanently masked and ineffective?
How will this safer immunotherapy revolutionize treatment for other hard-to-treat solid tumors?
VIR-5500 Delivers Unprecedented 65% Clinical Benefit Rate in Early mCRPC Trial; Vir and Astellas Announce $1.7B Global Collaboration
Overview
Vir Biotechnology has announced highly promising early results from its Phase 1 clinical trial of VIR-5500 for metastatic castration-resistant prostate cancer (mCRPC), presented at the 2026 ASCO Genitourinary Cancers Symposium. The findings generated considerable excitement in the oncology community, as the trial data showed a significant clinical benefit rate of 65% across all dose cohorts. Notably, 25% of patients achieved a partial response and 40% experienced stable disease for at least 24 weeks. These results highlight VIR-5500’s strong potential in treating mCRPC, offering new hope for patients with this challenging cancer.